Nanozymes in Ocular Disease Therapy: Research and Advancements

Haoyue Wang; Xue Liu; Jun Liu

doi:10.23977/medbm.2025.030115

Nanozymes in Ocular Disease Therapy: Research and Advancements

Download as PDF

DOI: 10.23977/medbm.2025.030115 | Downloads: 3 | Views: 150

Author(s)

Haoyue Wang ¹, Xue Liu ¹, Jun Liu ²

Affiliation(s)

¹ Department of Ophthalmology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
² Department of Ophthalmology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

Corresponding Author

Jun Liu

ABSTRACT

Nanozymes, a class of nanomaterials exhibiting enzyme-like catalytic activity, possess unique physicochemical properties and excellent biocompatibility, rendering them highly promising in the biomedical field. Recently, their application in ocular disease therapy has garnered significant attention. This review summarizes the recent advancements in the application of various types of nanozymes for ocular disease treatment, specifically focusing on catalase-mimicking, superoxide dismutase-mimicking, peroxidase-mimicking, and metal-organic framework (MOF) nanozymes. It also discusses the integration of nanozymes with drug delivery systems to enhance their therapeutic efficacy. Furthermore, this review addresses the current challenges hindering the clinical translation of nanozymes in ophthalmology and provides insights into future research directions.

KEYWORDS

Nanozymes; Ocular Diseases; Oxidative Stress; Drug Delivery; Therapeutic Mechanisms

CITE THIS PAPER

Haoyue Wang, Xue Liu, Jun Liu, Nanozymes in Ocular Disease Therapy: Research and Advancements. MEDS Basic Medicine (2025) Vol. 3: 98-108. DOI: http://dx.doi.org/10.23977/medbm.2025.030115.

REFERENCES

[1] Wei H, Wang E. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes. Chem Soc Rev. 2013 Jul 21;42(14):6060-6093.
[2] Jiang J, Li X, Li H, et al. Recent progress in nanozymes for the treatment of diabetic wounds. J Mater Chem B. 2023 Jul 26;11(29):6746-6761.
[3] GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-e160.
[4] Onugwu AL, Nwagwu CS, Onugwu OS, et al. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release. 2023 Feb;354:465-488.
[5] Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. AAPS J. 2010 Sep;12(3):348-60.
[6] Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009 May;26(5):1197-1216.
[7] Bourlais CL, Acar L, Zia H, et al. Ophthalmic drug delivery systems--recent advances. Prog Retin Eye Res. 1998 Jan;17(1):33-58.
[8] Hughes PM, Olejnik O, Chang-Lin JE, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005 Dec 13;57(14):2010-2032.
[9] Mofidfar M, Abdi B, Ahadian S, et al. Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. Int J Pharm. 2021 Sep 25;607:120924.
[10] Chen H, Jin Y, Sun L, et al. Recent Developments in Ophthalmic Drug Delivery Systems for Therapy of Both Anterior and Posterior Segment Diseases. Colloids Interface Sci. Commun. 2018;24:54–61.
[11] Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008 Feb;13(3-4):135-143.
[12] Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010 May;21(3):178-83.
[13] Kels BD, Grzybowski A, Grant-Kels JM. Human ocular anatomy. Clin Dermatol. 2015 Mar-Apr;33(2):140-146.
[14] Cunha-Vaz J. The blood-ocular barriers. Surv Ophthalmol. 1979 Mar-Apr;23(5):279-296.
[15] Nowell CS, Radtke F. Corneal epithelial stem cells and their niche at a glance. J Cell Sci. 2017 Mar 15;130(6):1021-1025.
[16] Li H, Dai F, Liu H, et al. Physicochemical properties and micro-interaction between micro-nanoparticles and anterior corneal multilayer biological interface film for improving drug delivery efficacy: the transformation of tear film turnover mode. Drug Deliv. 2023 Dec;30(1):2184312.
[17] Ruponen M, Urtti A. Undefined role of mucus as a barrier in ocular drug delivery. Eur J Pharm Biopharm. 2015 Oct;96:442-446.
[18] Webber, W., Jones, D. & Wright, P. Fluorophotometric measurements of tear turnover rate in normal healthy persons: Evidence for a circadian rhythm. Eye 1, 615–620 (1987).
[19] Lee VH, Robinson JR. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J Pharm Sci. 1979 Jun;68(6):673-684.
[20] Kim SH, Galbán CJ, Lutz RJ, et al. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):808-814.
[21] Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998 Dec;87(12):1479-1488.
[22] Runkle EA, Antonetti DA. The blood-retinal barrier: structure and functional significance. Methods Mol Biol. 2011;686:133-148.
[23] Youssef PN, Sheibani N, Albert DM. Retinal light toxicity. Eye (Lond). 2011 Jan;25(1):1-14.
[24] Shao M, Chai Y, Jiang Y, et al. Eye-Drop Nano-Formulation of Catalase Self-Assembled with Thiolated Chitosan for Effective Treatment of Dry Eye Disease. Adv Mater. 2025 May; 37(19):e2415353.
[25] Ge C, Fang G, Shen X, et al. Facet energy versus enzyme-like activities:the unexpected protection of palladium nanocrystals against oxidative damage[J]. ACS Nano, 2016, 10(11):10436-10445.
[26] Liu S, Teng S, Hui P, et al. Research Progress of Nanozymes in Ocular Disease Treatment. Chinese Journal of Applied Chemistry. 2024; 41(12):1679-1696.
[27] Liu S, Bai Q, Jiang Y, et al. Multienzyme-Like Nanozyme Encapsulated Ocular Microneedles for Keratitis Treatment. Small. 2024 May; 20(21):e2308403.
[28] Suresh Thangudu, Chia-Hao Su. Peroxidase Mimetic Nanozymes in Cancer Phototherapy: Progress and Perspectives. Biomolecules 2021, 11 (7), 1015.
[29] Wang Y, Li H, Guo L, et al. A cobalt-doped iron oxide nanozyme as a highly active peroxidase for renal tumor catalytic therapy[J]. RSC Adv, 2019, 9(33):18815-18822.
[30] Ma X, Zhao D, Wu P, et al. Metal-Organic Framework-Based Nanozymes and Their Applications in Bioanalysis. Chinese Journal of Analytical Chemistry. 2023;51(06):922-933.
[31] Yuan Xin, Xiong Jun, Wu Xiaoling, et al. Ultrasmall Ce-based metal–organic frameworks nanozyme with hydrolytic activity for boosting antibiofilm therapy. Chemical Engineering Journal, 2024, 480:148246.
[32] Wang C, Yang K, Li T, Jia L, Yan H, Wen J. The Construction of a Library of Nanozyme with High Nitrogen Content for Efficient Antibacterial Applications. Small. 2025 Apr;21(17):e2500558.
[33] Peng C, Pang R, Li J, Wang E. Current Advances on the Single-Atom Nanozyme and Its Bioapplications. Adv Mater. 2024 Mar;36(10):e2211724.
[34] Zhang Y, Shi Z, Shu Y, et al. Cerium Nanozyme‐Powered Hydrogel Microspheres Alleviate Thromboangiitis Obliterans Via Enhanced Stem Cell Therapy. Small. 2025;21(20):e2408748.
[35] Zou H. Research on Functional Cerium Oxide Nanozyme for the Treatment of Dry Eye Disease [D]. Wenzhou Medical University; 2023.
[36] Yau JW, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-564.
[37] Sun Y, Zhao X, Yang R, Xiao M, Liu W. α‐Lipoic Acid‐Based Nanozyme for Treating Acute Epilepsy. Advanced Functional Materials. 2024;35(3):2412633.
[38] Du M, Zhao X, Guo M, et al. Drugless peptide-based nanohybrids alleviate diabetic retinopathy by suppressing microglial activation and endothelial inflammation. Theranostics. 2025 Mar 3;15(9):3943-3960.
[39] Rui M, Mao J, Wu H, et al. Implantable Multifunctional Micro‐Oxygen Reservoir System for Promoting Vascular‐Osteogenesis Via Remodeling Regenerative Microenvironment. Advanced Science. 2024;12(3):2409636.
[40] Miserez A, Yu J, Mohammadi P. Protein-Based Biological Materials: Molecular Design and Artificial Production. Chem Rev. 2023 Mar 8;123(5):2049-2111.
[41] Xiang Y, Qiu Z, Ding Y, et al. Dexamethasone-loaded ROS stimuli-responsive nanogels for topical ocular therapy of corneal neovascularization. J Control Release. 2024 Aug;372:874-884.
[42] Jin Y, Cai D, Mo L, et al. Multifunctional nanogel loaded with cerium oxide nanozyme and CX3CL1 protein: Targeted immunomodulation and retinal protection in uveitis rat model. Biomaterials. 2024 Sep;309:122617.
[43] Kost OA, Beznos OV, Davydova NG, et al. Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation. Oxid Med Cell Longev. 2015; 2015: 5194239.
[44] Sheng S, Zhao H, Liu L, et al. MicroRNA-loaded antioxidant nanoplatforms for prevention and treatment of experimental acute and chronic uveitis. Biomaterials. 2025 Apr 20; 322:123353.
[45] Liang Y, Tian Y, Liu J, et al. Smart Bioorthogonal Catalytic Factory for Glaucoma Therapy. Nano Lett. 2025 Apr 2;25(13):5502-5511.
[46] Cao Y, Yin X, Wu L, et al. High-Efficiency Ocular Delivery of Brain-Derived Neurotrophic Factor and Oligomycin for Neuroprotection in Glaucoma. Adv Mater. 2025 May 13:e2500623.

Subscription

E-Mail Alert

Downloads:	1586
Visits:	78081

Nanozymes in Ocular Disease Therapy: Research and Advancements

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US